10X GENOMICS INC CLASS A (TXG)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for TXG
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| TXG | Director | 50 | ["Chair in Stem Cell Medicine at the University of Cambridge","Senior Research Fellow at the University of Cambridge","Previous Junior Research Fellow at University of Cambridge","Previous Teaching Fellow at University of Cambridge","Previous Director of Studies at University of Cambridge","Previous Director of Research at University of Cambridge’s Cavendish Laboratory","Co-chair of the Human Cell Atlas Organizing Committee","Co-chair of the board of directors of Human Cell Atlas, Inc.","Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline","Co-founder and Chief Scientific Officer of EnsoCell Therapeutics","Previous Head of Cellular Genetics at the Wellcome Sanger Institute","Previous Senior Group Leader at the Wellcome Sanger Institute","Previous Research Group Leader at EMBL","Previous Programme Leader at the MRC Laboratory of Molecular Biology","Beit Memorial Fellow at University College London","Member of the European Molecular Biology Organization","Fellow of the Academy of Medical Sciences and Royal Society","Fellow of the International Society of Computational Biology","Fellow of the American Academy of Arts and Sciences","Fellow of the National Academy of Medicine (USA)"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Sarah A. Teichmann, Ph.D. has served on our board of directors since July 2024. She has served as the Chair in Stem Cell Medicine at the University of Cambridge s Stem Cell Institute and Department of Medicine since April 2024 and as Senior Research Fellow at the University of Cambridge s Churchill College since October 2016, having previously served as Junior Research Fellow and then Teaching Fellow and Director of Studies at the University of Cambridge s Trinity College from 1999 to 2015 and Director of Research in the University of Cambridge s Cavendish Laboratory (Physics Department) from 2013 to April 2024. Dr. Teichmann has served as co-chair of the Human Cell Atlas (HCA) Organizing Committee since co-founding the HCA, an initiative to describe all cell types in the human body, in October 2016 and has served as co-chair of the board of directors of Human Cell Atlas, Inc., a nonprofit 501(c)(3) organization which supports the HCA, since April 2020. Additionally, Dr. Teichmann has served as Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline plc, a multinational pharmaceutical company, since January 2024, and as a co-founder, consultant, Chief Scientific Officer and board member of EnsoCell Therapeutics, a private drug discovery company using spatial genomics, artificial intelligence and machine learning methods, since September 2023. From February 2016 to December 2023, she served as Head of Cellular Genetics at the Wellcome Sanger Institute, where she also served as Senior Group Leader from February 2013 to April 2024 and as a member of the executive board from February 2016 to December 2023. From February 2013 to January 2016, she served as Research Group Leader at the European Molecular Biology Laboratory s (EMBL) European Bioinformatics Institute. From October 2001 to January 2013, she served as Programme Leader at the Medical Research Council s (MRC) Laboratory of Molecular Biology in Cambridge. Dr. Teichmann was a Beit Memorial Fellow at University College London from January 2000 to September 2001. She is a European Molecular Biology Organization (EMBO) member and a Fellow of the Academy of Medical Sciences and Royal Society, as well as a Fellow of the International Society of Computational Biology, the American Academy of Arts and Sciences, and the National Academy of Medicine (USA). Dr. Teichmann received a Ph.D. in Computational Genomics, as well as a B.A. and M.A. in Natural Sciences (Biochemistry), from the University of Cambridge. WE BELIEVE THAT DR. TEICHMANN IS QUALIFIED TO SERVE ON OUR BOARD OF DIRECTORS BECAUSE OF HER EXTENSIVE ACADEMIC AND INDUSTRY LEADERSHIP AND EXPERIENCE.